/C O R R E C T I O N - AbbVie/
Key Highlights
- ➤Temab-A plus bevacizumab posted 30% ORR in Phase 1 colorectal cancer
- ➤Temab-A colorectal combination median OS reached 14.7 months versus 10.2 standard care
- ➤ABBV-706 delivered 56% ORR and 12.4-month median OS in 2L+ SCLC
- ➤ABBV-969 produced ≥50% ctDNA reductions in 90% by cycle 3
- ➤ABBV-1480 monotherapy achieved 61.9% ORR and 15.2-month median PFS
Expert Statements
Daejin Abidoye, vice president, therapeutic area head of oncology, solid tumor and hematology, AbbVie
“The data we are presenting at ESMO reflects the progress being made through AbbVie's disciplined, biology-driven approach to oncology innovation. Across multiple tumor types and stages of development, we are seeing encouraging evidence of longer-term clinical benefit, promising outcomes in biomarker-defined patient populations, and the potential of novel combinations and next-generation platforms. Together, these findings reinforce our strategy of translating scientific insights into differentiated treatment approaches with the potential to meaningfully improve outcomes for patients living with cancer.”
In the news release, AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio, issued 18-Oct-2026 by AbbVie over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows: AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
* New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine * AbbVie's largest ESMO presence to date highlights longer-term survival data, combination and biomarker findings from multiple assets across various stages of development * Presentations across investigational and approved medicines to feature Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Emrelis™ (telisotuzumab vedotin-tllv) and Elahere(®)(mirvetuximab soravtansine-gynx) NORTH CHICAGO, Ill., Oct. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain. Spanning multiple tumor types, therapeutic modalities and stages of development, the presentations represent AbbVie's most expansive ESMO program to date.
Get started
Create a free account to read the full story.